首页> 外文OA文献 >Spironolactone in essential hypertension: evidence against its effect through mineralocorticoid antagonism.
【2h】

Spironolactone in essential hypertension: evidence against its effect through mineralocorticoid antagonism.

机译:螺内酯在原发性高血压中的作用:通过盐皮质激素拮抗作用对抗其作用的证据。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The effect of a six-week course of spironolactone 300 mg/day was examined in 25 unselected patients with essential hypertension. In the blood spironolactone produced a significant rise in urea and potassium concentrations and a fall in sodium and bicarbonate concentrations. In six patients blood pressure was normal at the end of the course, while in five patients there was almost no change. Studies of the effects of spironolactone on various indices usually affected by mineralocorticoids-namely, blood electrolytes, total body potassium, and rectal electrical properties-showed no differences between responding and non-responding patients. Mineralocorticoid excess therefore seems to be rarely responsible for essential hypertension and the influence of spironolactone cannot at present be fully explained.
机译:在25例未经选择的原发性高血压患者中,对6周疗程的300mg /天的螺内酯进行了检查。在血液中,螺内酯会明显增加尿素和钾的浓度,并降低钠和碳酸氢盐的浓度。六名患者在疗程结束时血压正常,而五名患者几乎没有变化。对螺内酯对通常受盐皮质激素影响的各种指标(即血液电解质,全身钾和直肠电特性)的影响的研究表明,有反应的患者和无反应的患者之间没有差异。因此,盐皮质激素的过量似乎很少引起原发性高血压,目前尚不能完全解释螺内酯的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号